KR101956335B1 - 히스톤 억제 - Google Patents

히스톤 억제 Download PDF

Info

Publication number
KR101956335B1
KR101956335B1 KR1020137016013A KR20137016013A KR101956335B1 KR 101956335 B1 KR101956335 B1 KR 101956335B1 KR 1020137016013 A KR1020137016013 A KR 1020137016013A KR 20137016013 A KR20137016013 A KR 20137016013A KR 101956335 B1 KR101956335 B1 KR 101956335B1
Authority
KR
South Korea
Prior art keywords
histone
sulfate
histones
group
oso
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137016013A
Other languages
English (en)
Korean (ko)
Other versions
KR20130121877A (ko
Inventor
로스 웬트워쓰 스티븐스
크리스토퍼 리차드 파리쉬
크레이그 제프리 프리만
티모시 존 센덴
Original Assignee
디 오스트레일리언 내셔널 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디 오스트레일리언 내셔널 유니버시티 filed Critical 디 오스트레일리언 내셔널 유니버시티
Publication of KR20130121877A publication Critical patent/KR20130121877A/ko
Application granted granted Critical
Publication of KR101956335B1 publication Critical patent/KR101956335B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
KR1020137016013A 2010-12-01 2011-11-29 히스톤 억제 Active KR101956335B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41882610P 2010-12-01 2010-12-01
US61/418,826 2010-12-01
PCT/AU2011/001550 WO2012071611A1 (en) 2010-12-01 2011-11-29 Histone inhibition

Publications (2)

Publication Number Publication Date
KR20130121877A KR20130121877A (ko) 2013-11-06
KR101956335B1 true KR101956335B1 (ko) 2019-03-08

Family

ID=46171086

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137016013A Active KR101956335B1 (ko) 2010-12-01 2011-11-29 히스톤 억제

Country Status (15)

Country Link
US (1) US9226939B2 (https=)
EP (1) EP2646037B1 (https=)
JP (2) JP2014501730A (https=)
KR (1) KR101956335B1 (https=)
CN (1) CN103402526B (https=)
AU (1) AU2011335881B2 (https=)
BR (1) BR112013013544B1 (https=)
CA (1) CA2819642C (https=)
DK (1) DK2646037T3 (https=)
ES (1) ES2710857T3 (https=)
HU (1) HUE043546T2 (https=)
IL (1) IL226667A (https=)
NZ (1) NZ611316A (https=)
SG (1) SG190438A1 (https=)
WO (1) WO2012071611A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3105593B2 (ja) 1991-10-18 2000-11-06 東海パルプ株式会社 パルパー制御装置
CN110446511B (zh) 2017-03-10 2024-04-02 北卡罗来纳大学查珀尔希尔分校 短效的基于肝素的抗凝血剂化合物和方法
WO2019010216A1 (en) 2017-07-03 2019-01-10 The University Of North Carolina At Chapel Hill ENZYMATIC SYNTHESIS OF HOMOGENEOUS CHONDROITIN SULFATE OLIGOSACCHARIDES
JP7495061B2 (ja) 2017-11-03 2024-06-04 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 抗炎症作用を有する硫酸化オリゴ糖
CN111479574B (zh) * 2017-12-15 2024-02-09 澳大利亚国立大学 用于治疗和预防细胞外组蛋白介导的病理的化合物
CN112437667B (zh) * 2018-06-20 2024-05-28 北卡罗来纳大学查珀尔希尔分校 细胞保护方法和组合物
WO2020033824A1 (en) * 2018-08-09 2020-02-13 University Of Vermont And State Agricultural College Inhibitors of acute severe inflammatory conditions
WO2020172698A1 (en) * 2019-02-25 2020-09-03 The Australian National University Compounds for treating and preventing net associated complications
WO2021097345A1 (en) 2019-11-13 2021-05-20 The University Of North Carolina At Chapel Hill Heparan sulfate (hs) oligosaccharides effect in liver ischemia reperfusion injury
WO2022116981A1 (zh) * 2020-12-01 2022-06-09 远大医药（中国）有限公司 一种聚阴离子纤维二糖苷类化合物的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033726A1 (en) * 1995-04-28 1996-10-31 The Australian National University Preparation and use of sulfated oligosaccharides
US20090117099A1 (en) * 2007-11-06 2009-05-07 Oklahoma Medical Research Foundation Extracellular histones as biomarkers for prognosis and molecular targets for therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847338A (en) 1985-03-28 1989-07-11 University Of Iowa Research Foundation Low molecular weight heparin fragments as inhibitors of complement activation
DK505488D0 (da) * 1987-12-21 1988-09-09 Bar Shalom Daniel Middel og anvendelse af samme
US5583121A (en) * 1994-01-12 1996-12-10 Michigan State University Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
CA2158715C (en) 1994-09-21 2005-11-08 Rodney Browitt A precipitator
WO1999004826A1 (en) 1997-07-24 1999-02-04 The Australian National University Method for detection of fibrin clots
ITMI20021294A1 (it) * 2002-06-12 2003-12-12 Inalco Spa Polisaccaridi batterici o-solfatati e loro uso
US20050282775A1 (en) 2004-06-16 2005-12-22 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
US7468358B2 (en) * 2004-06-16 2008-12-23 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome
WO2006015171A2 (en) * 2004-07-28 2006-02-09 The Texas A & M University System Use of glycosoaminoglycans for the prevention and treatment of sepsis
NZ562855A (en) 2005-04-29 2010-01-29 Univ Australian A method of forming an injectable radioactive composition of a carbon encapsulated radioactive particulate
EP1747785A1 (en) * 2005-07-28 2007-01-31 Istituto Clinico Humanitas Cyclodextrins for blood detoxification
AU2006318216C1 (en) * 2005-11-28 2012-02-16 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
WO2007095688A1 (en) 2006-02-23 2007-08-30 The Australian National University Methods for increasing the number of circulating cells
GB2450087A (en) * 2007-06-11 2008-12-17 Diosamine Dev Corp Use of sulphated saccharides in the treatment of inflammatory and/or auto-immune diseases
CA2721836C (en) 2008-04-24 2017-04-11 The Australian National University Methods for radiolabelling macromolecules
JP2011256111A (ja) * 2008-10-03 2011-12-22 Hayashibara Biochem Lab Inc 敗血症の予防及び治療剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033726A1 (en) * 1995-04-28 1996-10-31 The Australian National University Preparation and use of sulfated oligosaccharides
US20090117099A1 (en) * 2007-11-06 2009-05-07 Oklahoma Medical Research Foundation Extracellular histones as biomarkers for prognosis and molecular targets for therapy

Also Published As

Publication number Publication date
DK2646037T3 (en) 2019-03-04
US9226939B2 (en) 2016-01-05
AU2011335881A1 (en) 2013-06-20
US20130338097A1 (en) 2013-12-19
KR20130121877A (ko) 2013-11-06
CA2819642A1 (en) 2012-06-07
NZ611316A (en) 2014-12-24
ES2710857T3 (es) 2019-04-29
HUE043546T2 (hu) 2019-08-28
EP2646037A1 (en) 2013-10-09
JP2016193917A (ja) 2016-11-17
EP2646037B1 (en) 2019-01-09
WO2012071611A1 (en) 2012-06-07
SG190438A1 (en) 2013-07-31
CN103402526B (zh) 2016-01-20
JP6142039B2 (ja) 2017-06-07
BR112013013544B1 (pt) 2020-09-29
CN103402526A (zh) 2013-11-20
EP2646037A4 (en) 2015-03-18
IL226667A (en) 2017-02-28
CA2819642C (en) 2019-07-16
JP2014501730A (ja) 2014-01-23
BR112013013544A2 (pt) 2016-10-11
AU2011335881B2 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
KR101956335B1 (ko) 히스톤 억제
EP0589556A2 (en) Carbohydrate-based anti-inflammatory agents
Beuth et al. Inhibition of liver tumor cell colonization in two animal tumor models by lectin blocking with D-galactose or arabinogalactan
US20080112955A1 (en) Method and composition for preventing pain in sickle cell patients
Kuypers et al. Interaction of an annexin V homodimer (Diannexin) with phosphatidylserine on cell surfaces and consequent antithrombotic activity
JP2013519706A (ja) 癌転移を予防するための方法
JPH06500330A (ja) 新規な炭水化物をベースにした抗炎症剤
CZ341097A3 (cs) Sulfatované oligosacharidy, způsob jejich výroby a použití
JPH09511233A (ja) 細胞接着インヒビターとしての置換ラクトース誘導体
JPH10507742A (ja) シアル酸／フコースベースの医薬
JP2021517582A (ja) 細胞外ヒストンによって媒介される病理を処置及び予防するための化合物
CN118178612A (zh) 抗凝蛋白质及其治疗与中性粒细胞活化相关的疾病的用途
US20060217343A1 (en) 2-Polycyclic propynyl adenosine analogs having A2A agonist activity
CN104302296A (zh) 用于治疗血友病a和/或冯维勒布兰德病的糖组合物
JP2004059506A (ja) セレクチン及びケモカインに作用する過硫酸化オリゴ糖
Li et al. Sialic acid-functionalized targeted drug delivery systems: advances in tumor and inflammation therapy by binding to Siglecs or selectin receptors.
CZ238796A3 (en) Pharmacological preparation containing oligosaccharide and the use of such oligosaccharide
HK1188125B (en) Use of polyanions to inhibit the cytotoxic activity of histones in the treatment of sepsis
HK1188125A (en) Use of polyanions to inhibit the cytotoxic activity of histones in the treatment of sepsis
JP2003535965A (ja) インフルエンザウイルス結合性シアル化オリゴ糖含有物質およびその用途
WO2020179104A1 (ja) α－ガラクトシルセラミド及び／又はα－ガラクトシルセラミドでパルスされた樹状細胞を含有する医薬組成物
JP6712042B1 (ja) α−ガラクトシルセラミド及び／又はα−ガラクトシルセラミドでパルスされた樹状細胞を含有する医薬組成物
CN118615430A (zh) 一种蛋白纳米复合物、含其的靶向递送系统及其应用
JP2020143036A (ja) リポソーム、およびそれを含有する抗マラリア薬
US20050214248A1 (en) Non-glycosylated polyacrylamide conjugates and their use for cytoprotection

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000